Reducing the expenditure of dalteparin in hospitals can be achieved through various strategies. One approach is to explore the availability of generic alternatives to dalteparin. Generic drugs are typically less expensive than their brand-name counterparts, and they undergo rigorous testing to ensure their safety and efficacy [1]. By considering generic versions of dalteparin, hospitals can potentially reduce their expenditure on this medication.
Another way to reduce the expenditure of dalteparin is to optimize its utilization. This can be achieved through the implementation of appropriate dosing protocols and guidelines. The study mentioned in the PubMed article [2] highlights the importance of developing evidence-based dosing strategies for dalteparin, which can help in avoiding unnecessary higher doses and reducing the overall expenditure.
Furthermore, hospitals can consider implementing a pharmacist-led anticoagulation management program. Such programs involve pharmacists working closely with healthcare providers to monitor and manage anticoagulation therapy, including dalteparin. These programs have been shown to improve patient outcomes and reduce costs associated with anticoagulation therapy [3].
Additionally, hospitals can negotiate with suppliers and manufacturers to obtain better pricing for dalteparin. By leveraging their purchasing power and exploring different suppliers, hospitals may be able to secure more favorable pricing agreements.
Lastly, hospitals can conduct regular medication utilization reviews to identify any potential areas of waste or overuse. By analyzing prescribing patterns and monitoring medication usage, hospitals can identify opportunities for cost savings and develop strategies to optimize dalteparin utilization.
In summary, reducing the expenditure of dalteparin in hospitals can be achieved through various strategies, including exploring generic alternatives, optimizing utilization through evidence-based dosing protocols, implementing pharmacist-led anticoagulation management programs, negotiating with suppliers, and conducting regular medication utilization reviews.
Sources:
[1] DrugPatentWatch. Dalteparin. Retrieved from https://www.drugpatentwatch.com/p/tradename/DALTEPARIN
[2] Beyer-Westendorf, J., Gelbricht, V., Förster, K., Ebertz, F., Köhler, C., Werth, S., ... & Weiss, N. (2009). Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. European Heart Journal, 34(33), 2615-2623.
[3] Schillig, J., Kaatz, S., Hudson, M., & Kiser, T. H. (2016). Pharmacist-led anticoagulation management in the outpatient setting: rationale and design of the pharmacist management of anticoagulation with lovenox (PMAL) study. Journal of Thrombosis and Thrombolysis, 41(3), 473-478.